Enanta Pharma (ENTA) Tops Q4 EPS by 14c

Enanta Pharma (NASDAQ: ENTA) reported Q4 EPS of ($0.87), $0.14 better than the analyst estimate of ($1.01). Revenue for the quarter came in at $15.13 million versus the consensus estimate of $15.97 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• Lumexa Imaging Holdings, Inc. (LMRI) Reports In-Line Q2 EPS; Offers Guidance
• FGI Industries Ltd (FGI) Tops Q2 EPS by 59c